treosulfan has been researched along with Recrudescence in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M | 1 |
| Behre, G; Döhring, C; Franke, GN; Grimm, J; Hille, A; Jentzsch, M; Linke, R; Niederwieser, D; Pönisch, W; Schwind, S; Vucinic, V | 1 |
| Apel, A; Bernardi, M; Bonini, C; Ciceri, F; Danylesko, I; Greco, R; Lo Russo, A; Lupo Stanghellini, MT; Nagler, A; Peccatori, J; Shem-Tov, N; Shimoni, A; Vago, L; Yerushalmi, R | 1 |
| Algeri, M; Aricò, M; Basso, G; Caniglia, M; Cesaro, S; Di Bartolomeo, P; Fagioli, F; Favre, C; Giardino, S; Locatelli, F; Marzollo, A; Merli, P; Messina, C; Pillon, M; Porta, F; Prete, A; Rabusin, M; Ripaldi, M; Rovelli, A; Saglio, F; Sieni, E; Zecca, M; Ziino, O | 1 |
| Frączkiewicz, J; Gajek, K; Kałwak, K; Mielcarek-Siedziuk, M; Raciborska, A; Rosa, M; Rybka, B; Ryczan-Krawczyk, R; Salamonowicz, M; Ślęzak, A; Ussowicz, M; Wawrzyniak-Dzierżek, E; Węcławek-Tompol, J | 1 |
| Balleisen, L; Basara, N; Behre, G; Casper, J; Christopeit, M; Ganser, A; Hinke, A; Hinke, R; Kahl, C; Koenigsmann, M; Metzner, B; Mohren, M; Niederwieser, D; Reichle, A; Sayer, HG; Stadler, M; Theurich, S; Uharek, L | 1 |
| Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B | 1 |
| Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C | 1 |
| Beelen, DW; Casper, J; Elmaagacli, AH; Freund, M; Gromke, T; Hilgendorf, I; Junghanss, C; Pichlmeier, U; Trenschel, R; Wolff, D | 1 |
| Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE | 1 |
| Brossart, P; Chemnitz, JM; Hallek, M; Holtick, U; Krause, A; Scheid, C; Shimabukuro-Vornhagen, A; Theurich, S; von Lilienfeld-Toal, M | 1 |
| Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR | 1 |
| Belau, A; Fuxius, S; Heidrich-Lorsbach, E; Heuser, T; Klare, P; Kölbl, H; Mahner, S; Markmann, S; Oskay-Özcelik, G; Ruhmland, B; Sehouli, J; Sommer, H | 1 |
| Becker, E; Casper, J; Franke, A; Freund, M; Heim, M; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M | 1 |
| Basara, N; Baumgart, J; Beelen, DW; Casper, J; Fauser, AA; Freund, M; Hahn, JR; Hertenstein, B; Hilger, RA; Holler, E; Mylius, HA; Pichlmeier, U; Scheulen, ME; Trenschel, R | 1 |
| Baumgart, J; Casper, J; Freund, M; Grobe, N; Hähling, D; Hartung, G; Hilgendorf, I; Junghanss, C; Kahl, C; Lück, A; Pichlmeier, U; Steiner, B; Wilhelm, S; Wolff, D | 1 |
| Atanackovic, D; Ayuk, F; Dahlke, J; Kröger, N; Nagler, A; Panse, J; Renges, H; Schieder, H; Shimoni, A; Wolschke, C; Zabelina, T; Zander, A | 1 |
| Blau, IW; Blau, O; Göldner, H; Hopfenmüller, W; Knauf, W; Leschinger, N; Schmidt-Hieber, M; Thiel, E | 1 |
| Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K | 1 |
| Casper, J; Freund, M; Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Wojnar, J | 1 |
12 trial(s) available for treosulfan and Recrudescence
| Article | Year |
|---|---|
Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Male; Melphalan; Neuroblastoma; Recurrence; Stem Cell Transplantation; Survival Rate; Thiotepa | 2019 |
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease Progression; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Risk Factors; Rituximab; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.
Topics: Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents, Alkylating; Busulfan; Constipation; Drug Administration Schedule; Fatigue; Female; Humans; Leukopenia; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prospective Studies; Quality of Life; Recurrence; Surveys and Questionnaires; Treatment Outcome | 2012 |
High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.
Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pharmacokinetics; Recurrence; Risk Assessment; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2005 |
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Recurrence; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2008 |
10 other study(ies) available for treosulfan and Recrudescence
| Article | Year |
|---|---|
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2023 |
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2019 |
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; Hematopoietic Stem Cell Transplantation; HLA-C Antigens; Humans; Leukemia, Myeloid, Acute; Ligands; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2017 |
Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Infant; Italy; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2018 |
Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Comorbidity; Disease-Free Survival; Humans; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2011 |
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2012 |
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Recurrence; Regression Analysis; Remission Induction; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |